Key facts
- Rznomics (KRX: 476830)’s last known valuation is $120.3M (Jun 2022).
- It has raised $95.5M; the latest was IPO ($31.5M) in Dec 2025.
- Status: Publicly Held.
- ·Watchlist + deal alerts for Rznomics (KRX: 476830)
- ·The full record, as it builds
Funding rounds
No funding rounds for Rznomics (KRX: 476830) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rznomics (KRX: 476830)
Rznomics Inc is engaged in research and development of biopharmaceuticals, developing gene therapy drugs based on RNA substitution enzyme platform and self-cycling RNA platform technologies, and commercializing them through technology transfer.
- Sector
- Healthcare
- HQ
- Yongin, South Korea
- Founded
- 2017
- Employees
- 40
- Website
- rznomics.com/
- Ownership
- Publicly Held
Rznomics (KRX: 476830) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rznomics (KRX: 476830) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rznomics (KRX: 476830) in its N-PORT filings yet. We sweep new filings monthly.